FOLH1 and Familial prostate cancer: The BIOPSTAGE trial investigates the added diagnostic value of combining prostate-specific membrane antigen positron emission tomography (PSMA PET) with multiparametric MRI (mpMRI) for non-invasive detection of clinically significant prostate cancer (csPCa).